Search

New Eye Care Support Pathway wins cross-sector backing for transforming the way people with care needs and sight loss are helped emotionally and practically.

• News

Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.

These frequently asked questions should provide a response for most of the queries you might raise.

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

Nurturing a new generation of scientists is a vital investment in the future of retinal disease research, so we are delighted to be funding, in collaboration with the Macular Society, a new PhD studentship at Oxford University, supervised by Professor Robert MacLaren.

• Case study - research
• Written

Jenny Dewing is a postdoctoral researcher working on a Retina UK-funded project with Dr Arjuna Ratnayaka at the University of Southampton.

• Case study - research
• Written

Simon spent 40 years as a consultant ophthalmic surgeon at the North Hampshire Hospital in Basingstoke.

• Trustee
• Written

Vanessa is the General Counsel at the Alan Turing Institute, the UK’s national data science and artificial intelligence research institute.

• Trustee
• Written

Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.

• e-Newsletter
• Audio
• Written

These are some of the most commonly asked questions about genetic testing and counselling.